Global Vaccines Market Boost From Prevnar13: companiesandmarkets.com

LONDON--(BUSINESS WIRE)-- The global vaccines market was valued at $28 billion in 2010, and is expected to reach $56.7 billion in 2017, according to a new report available on companiesandmarkets.com.

Adult and Adolescent Vaccines Market to 2017 - Accelerated Development and Introduction Plans (ADIP) by GAVI Alliance to Drive Growth

http://www.companiesandmarkets.com/Market-Report/adult-and-adolescent-vaccines-market-to-2017-accelerated-development-and-introduction-plans-%28adip%29-by-gavi-alliance-to-drive-growth-634002.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2

The vaccines market showed a turnaround after the resounding success of Prevnar13, the first blockbuster vaccine. The success of premium priced vaccines such as Prevnar13 has prompted big pharmaceutical players such as Pfizer and AstraZeneca to invest in the vaccines industry, which promises safe revenues due to a lack of threat from generics.

The shortage of Prevnar in 2001 caused a panic in the US due to increasing concerns about the rise in incidence of meningitis and pneumonia. Wyeth (now Pfizer) had only 60% of production capacity available for distribution. Such shortages not only decrease sales of the vaccines but also increase the incidence of diseases.

Analysis shows that licensing and co-development agreements are characteristic of the global vaccines market, where technologies and development platforms are highly dispersed among small and big companies. Smaller vaccine companies that do not have the financial muscle to compete against the top vaccine players make use of their technologies to generate revenues through royalties and through other revenue sharing agreements. Also, a number of public-private partnerships help the vaccines industry to develop interventions for new diseases.

The global vaccines industry is a difficult industry for smaller companies to succeed in due to the high development costs required for licensing, acquisitions, marketing and manufacturing. Vaccine companies with promising candidates in the pipeline engage in out-licensing agreements with the top players, who in turn provide marketing, sales, and regulatory support.

The report provides insights into the global vaccines market, forecast until 2017. The report provides an in-depth analysis of five vaccines, which include pneumococcal, seasonal flu, human papillomavirus, hepatitis A and hepatitis B. The report examines the immunization schedules for the covered vaccines.

Report Details: http://www.companiesandmarkets.com/Market-Report/adult-and-adolescent-vaccines-market-to-2017-accelerated-development-and-introduction-plans-%28adip%29-by-gavi-alliance-to-drive-growth-634002.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2



CONTACT:

Companies & Markets
Paul Chapman
Press Office
[email protected]
London (UK): +44 (0) 203 086 8600

KEYWORDS:   United Kingdom  Europe

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Communications  Other Communications  Medical Supplies

MEDIA:

Logo
 Logo

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.